TSE:4534Pharmaceuticals
Mochida Pharmaceutical (TSE:4534) Q3 EPS Decline Versus Q3 2025 Tests Earnings Recovery Narrative
Mochida Pharmaceutical (TSE:4534) has posted its Q3 2026 numbers with revenue of ¥32,502 million and basic EPS of ¥70.13, set against a trailing twelve month picture that includes net income of ¥6,422 million. The company has seen revenue move from ¥29,635 million in Q3 2025 to ¥32,502 million in Q3 2026, while basic EPS shifted from ¥78.42 to ¥70.13 over the same period. This gives investors a clear view of how the top line and EPS trend are feeding into the latest quarter. With a trailing...